Device Trial Radar · NCT06188585
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
278
Planned (sponsor's estimate)
Start
Jun 21, 2024
Primary completion
Aug 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Medtronic - MITGPublic (MDT)
- Sponsor type
- Industry
- Collaborators
- North American Science Associates Ltd.
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.
Conditions
- Acute Gastrointestinal Bleeding
Interventions
UI-EWDDevice
Hemostatic powder administered at index endoscopy
Conventional therapyDevice
Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy
Primary outcomes
What the sponsor says the trial is designed to measure.
- No further bleeding during the 7-day period after hemostatic treatmentTime frame: 7 days
Locations
15 sites in 7 countries. Site status is shown where the registry gives one.
Yale
New Haven, Connecticut · Recruiting
RUSH University
Chicago, Illinois · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.